Daily non-political popular news in brief.

Other highlights in the Nov. 13 JNCI

Other highlights in the Nov. 13 JNCI include a simple model to predict breast cancer risk, the link between smoking and rectal cancer, research into how a cancer drug causes heart damage, a gene that may inhibit lung cancer, BRCA1's influence on drug response, and the difficulties assigning patients to cancer subtypes.

Read more »

Keywords: highlights, nov, jnci, highlight

« Previous | Next »

Similar news on "Other highlights in the Nov. 13 JNCI":

1. Other highlights in the November 15 JNCI
   11-14-2006 · EurekAlert!
   Other highlights in the Nov. 15 JNCI include the impact of weight on colon cancer outcomes, a combination therapy that increases ovarian cancer survival, impact of aging on breast cancer risk and a molecule that can target the tumor vascular system.
   Similar news · Read more »
   
2. Other Highlights in the Nov. 27 JNCI
   11-27-2007 · EurekAlert!
   Also in the Nov. 27 JNCI are risk estimates for breast cancer in men with BRCA mutations, refined carbohydrates and their association with prostate tumor growth, the relationship between HPV, smoking, and drinking in head and neck cancer patients, and drugs that can boost the power of cancer-killing viruses.
   Similar news · Read more »
   
3. Other highlights in the February 21 JNCI
   02-20-2007 · EurekAlert!
   Also in the February 21 JNCI are a new screening method for those at risk for a hereditary colorectal cancer, a mouse study of low-dose bisphosphonates' antitumor effects, and research on a protein that is active in metastasis suppression.
   Similar news · Read more »
   
4. Other highlights in the Aug. 7 JNCI
   08-07-2007 · EurekAlert!
   Also in the Aug. 7 JNCI are a study showing vitamins and minerals do not improve liver cancer survival, another study on testicular cancer survivors' survival rates for second cancers, a gene expression pattern that predicts lung cancer prognosis and epigenetic changes in Wilms tumor.
   Similar news · Read more »
   
5. Capacity and consent in Canada
   11-19-2007 · EurekAlert!
   An editorial in the Nov. 20, 2007 issue of the Canadian Medical Association Journal uses cases involving patients in two Canadian provinces to highlight the broadly divergent capacity and consent legislation in Canada.
   Similar news · Read more »
   
6. Other highlights in the April 4 JNCI
   04-03-2007 · EurekAlert!
   Also in the April 4 JNCI are a study on the risk of noncancer death among testicular cancer survivors, a report that celecoxib does not prevent cancer in Barrett's esophagus patients, and a link between bladder cancer and androgens in mice.
   Similar news · Read more »
   
7. Other highlights from the June 6 JNCI
   06-05-2007 · EurekAlert!
   Also in the June 6 JNCI is an association between aspirin use and decreased risk of cancer, a protein that suppresses tumor growth and cell migration, the incidence of a rare cancer in Denmark, and a protein that is not associated with inflammation, but not breast cancer.
   Similar news · Read more »
   
8. Other highlights in the Dec. 11 JNCI
   12-11-2007 · EurekAlert!
   Also in the Dec. 11 JNCI are a drug that may reduce breast cancer recurrence, the risk of cancer after a blood transfusion, the association between PSA testing and prostate cancer diagnoses, and cancer risk among NBN mutation carriers.
   Similar news · Read more »
   
9. Other highlights in the November 1 JNCI
   10-31-2006 · EurekAlert!
   Other highlights in the November 1 issue of JNCI include a review of statins and fibrates for action against melanoma, a study of a virus that kills brain tumors in mice, an antibody that decreases ovarian cancer growth in mice and a study that describes the use of the immunohistochemical assay in predicting clinical trial results for breast cancer patients.
   Similar news · Read more »
   
10. Other highlights in the May 2 JNCI
    05-01-2007 · EurekAlert!
    Also in the May 2 JNCI is a follow-up to the Italian Randomized Tamoxifen Trial, a study on treating breast cancer patients with three HER inhibitor drugs, an increase in survival rates for indolent lymphoma patients using a chemotherapy-rituximab combination, and new lung cancer risk prediction models.
    Similar news · Read more »